围术期收缩压变异性与经导管颅内血管取栓术患者术后预后的关联分析

注册号:

Registration number:

ChiCTR2600121822 

最近更新日期:

Date of Last Refreshed on:

2026-04-03 14:26:01 

注册时间:

Date of Registration:

2026-04-03 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

围术期收缩压变异性与经导管颅内血管取栓术患者术后预后的关联分析

Public title:

Association Analysis of Perioperative Systolic Blood Pressure Variability with Postoperative Prognosis in Patients Undergoing Transcatheter Intracranial Thrombectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

颅内血管取栓术围术期理想血压水平的研究

Scientific title:

Study on the Ideal Blood Pressure Level During Perioperative Period of Intracranial Vascular Thrombectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨茜茜 

研究负责人:

杨茜茜 

Applicant:

Yang Qianqian 

Study leader:

Yang Qianqian 

申请注册联系人电话:

Applicant telephone:

+86 189 6132 2716

研究负责人电话:

Study leader's
telephone:

+86 189 6132 2716

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1161880131@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1161880131@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省连云港市振华东路6号

研究负责人通讯地址:

江苏省连云港市振华东路6号

Applicant address:

No. 6 Zhenhuang East Road, Lianyungang City, Jiangsu Province, China

Study leader's address:

No. 6 Zhenhuang East Road, Lianyungang City, Jiangsu Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

连云港市第一人民医院

Applicant's institution:

The First People's Hospital of Lianyungang

研究负责人所在单位:

连云港市第一人民医院

Affiliation of the Leader:

The First People's Hospital of Lianyungang

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-20260119007-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

连云港市第一人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First People's Hospital of Lianyungang

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-26 00:00:00

伦理委员会联系人:

连云港市第一人民医院医学伦理委员会

Contact Name of the ethic committee:

Medical Ethics Committee of the First People's Hospital of Lianyungang

伦理委员会联系地址:

江苏省连云港市振华东路6号

Contact Address of the ethic committee:

No. 6 Zhenhuang East Road, Lianyungang City, Jiangsu Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 518 8576 7557

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

连云港市第一人民医院

Primary sponsor:

The First People's Hospital of Lianyungang

研究实施负责(组长)单位地址:

江苏省连云港市振华东路6号

Primary sponsor's address:

No. 6 Zhenhuang East Road, Lianyungang City, Jiangsu Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

连云港市第一人民医院

具体地址:

江苏省连云港市振华东路6号

Institution
hospital:

The First People's Hospital of Lianyungang

Address:

No. 6 Zhenhuang East Road, Lianyungang City, Jiangsu Province, China

经费或物资来源:

自筹

Source(s) of funding:

self

研究疾病:

急性脑卒中  

Target disease:

Acute stroke

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

探讨急性缺血性卒中患者行颅内血管取栓术围术期血压对预后的影响  

Objectives of Study:

To investigate the effect of perioperative blood pressure on prognosis in patients with acute ischemic stroke undergoing intracranial vascular thrombectomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.基线美国国立卫生研究院卒中量表(National Institutes of Health Stroke Scale, NIHSS)评分>28分; 2.既往有出血性疾病或头颅CT提示颅内出血及活动性出血证据; 3.严重心、肝、肾或肺功能不全; 4.核心梗死区域范围过大,经治疗团队判断手术无获益; 5.术后改良脑梗死溶栓分级(modified Thrombolysis In Cerebral Infarction,mTICI)未达到2b级及以上; 6. 围术期血压监测数据缺失,术后90天随访失联患者。

Exclusion criteria:

1. Baseline National Institutes of Health Stroke Scale (NIHSS) score > 28; 2. History of hemorrhagic disorders, or intracranial hemorrhage and evidence of active bleeding shown on head CT; 3. Severe cardiac, hepatic, renal, or pulmonary insufficiency; 4. Extensive core infarct volume with no surgical benefit judged by the treatment team; 5. Postoperative modified Thrombolysis in Cerebral Infarction (mTICI) grade not reaching 2b or higher; 6. Patients with missing perioperative blood pressure monitoring data or loss to follow-up at 90 days postoperatively.

研究实施时间:

Study execute time:

From 2026-04-04 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-04 00:00:00 To 2026-10-01 00:00:00

干预措施:

Interventions:

组别:

低围术期血压变异组

样本量:

111

Group:

Low perioperative blood pressure variability group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

中围术期血压变异组

样本量:

110

Group:

Medium perioperative blood pressure variability group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

高围术期血压变异组

样本量:

110

Group:

High perioperative blood pressure variability group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

连云港市第一人民医院 

单位级别:

三甲 

Institution
hospital:

The First People's Hospital of Lianyungang

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后90天改良Rankin量表(mRS)评分

指标类型:

主要指标

Outcome:

Modified Rankin Scale (mRS) score at 90 days postoperatively

Type:

Primary indicator

测量时间点:

术后90天

测量方法:

Measure time point of outcome:

90 days postoperatively

Measure method:

指标中文名:

症状性出血

指标类型:

主要指标

Outcome:

symptomatic intracranial hemorrhage

Type:

Primary indicator

测量时间点:

术后90天

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture, EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-04-03 14:25:39